CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, Lanier LL, Venstrom JM.
Du J, et al. Among authors: zhou l.
Cancer Immunol Res. 2014 Sep;2(9):878-89. doi: 10.1158/2326-6066.CIR-13-0158. Epub 2014 Jun 23.
Cancer Immunol Res. 2014.
PMID: 24958280
Free PMC article.